KR102245985B1 - Pi3k 억제제와 c-met 억제제의 조합물 - Google Patents

Pi3k 억제제와 c-met 억제제의 조합물 Download PDF

Info

Publication number
KR102245985B1
KR102245985B1 KR1020157003716A KR20157003716A KR102245985B1 KR 102245985 B1 KR102245985 B1 KR 102245985B1 KR 1020157003716 A KR1020157003716 A KR 1020157003716A KR 20157003716 A KR20157003716 A KR 20157003716A KR 102245985 B1 KR102245985 B1 KR 102245985B1
Authority
KR
South Korea
Prior art keywords
compound
combination
methyl
met
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157003716A
Other languages
English (en)
Korean (ko)
Other versions
KR20150043328A (ko
Inventor
지오르다노 카포니그로
시종 후앙
조셉 레하르
후이-친 왕
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150043328A publication Critical patent/KR20150043328A/ko
Application granted granted Critical
Publication of KR102245985B1 publication Critical patent/KR102245985B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157003716A 2012-08-16 2013-08-14 Pi3k 억제제와 c-met 억제제의 조합물 Expired - Fee Related KR102245985B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683790P 2012-08-16 2012-08-16
US61/683,790 2012-08-16
PCT/US2013/054848 WO2014028566A1 (en) 2012-08-16 2013-08-14 Combination of pi3k inhibitor and c-met inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012172A Division KR20210049187A (ko) 2012-08-16 2013-08-14 Pi3k 억제제와 c-met 억제제의 조합물

Publications (2)

Publication Number Publication Date
KR20150043328A KR20150043328A (ko) 2015-04-22
KR102245985B1 true KR102245985B1 (ko) 2021-04-30

Family

ID=49004065

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157003716A Expired - Fee Related KR102245985B1 (ko) 2012-08-16 2013-08-14 Pi3k 억제제와 c-met 억제제의 조합물
KR1020217012172A Ceased KR20210049187A (ko) 2012-08-16 2013-08-14 Pi3k 억제제와 c-met 억제제의 조합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217012172A Ceased KR20210049187A (ko) 2012-08-16 2013-08-14 Pi3k 억제제와 c-met 억제제의 조합물

Country Status (14)

Country Link
US (5) US20150216870A1 (enExample)
EP (1) EP2885003B1 (enExample)
JP (3) JP2015529194A (enExample)
KR (2) KR102245985B1 (enExample)
CN (1) CN105050623B (enExample)
AU (4) AU2013302702A1 (enExample)
BR (1) BR112015002528A2 (enExample)
CA (1) CA2879704A1 (enExample)
ES (1) ES2901712T3 (enExample)
HK (1) HK1211476A1 (enExample)
IN (1) IN2015DN00528A (enExample)
MX (1) MX369518B (enExample)
RU (1) RU2705095C2 (enExample)
WO (1) WO2014028566A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI547493B (zh) 2011-09-27 2016-09-01 諾華公司 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014203152A1 (en) * 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SG10201900648SA (en) 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
WO2016092508A1 (en) 2014-12-12 2016-06-16 Massachusetts General Hospital Treatment of breast cancer brain metastases
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
US20230065577A1 (en) * 2019-12-20 2023-03-02 Recurium Ip Holdings, Llc Combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109605A1 (en) 2008-03-05 2009-09-11 Novartis Ag Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
US20100267742A1 (en) 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
WO2012062694A1 (en) 2010-11-08 2012-05-18 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0719333A2 (pt) * 2006-11-22 2014-02-04 Incyte Corp Midazotriazinas e imidazopirimidinas como inbidores de cinase
EP2129379B1 (en) * 2007-02-20 2019-04-10 Novartis AG Imidazoquinolines as dual lipid kinase and mtor inhibitors
BRPI0912882A2 (pt) * 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
JP2011527703A (ja) * 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109605A1 (en) 2008-03-05 2009-09-11 Novartis Ag Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
US20100267742A1 (en) 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
WO2012062694A1 (en) 2010-11-08 2012-05-18 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hua C. Gong 외. Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer. International Journal of Proteomics. Vol. 2011, 2011, pp. 1-13*

Also Published As

Publication number Publication date
US20200253980A1 (en) 2020-08-13
WO2014028566A1 (en) 2014-02-20
JP6644042B2 (ja) 2020-02-12
KR20210049187A (ko) 2021-05-04
US20190083500A1 (en) 2019-03-21
AU2018201725A1 (en) 2018-04-05
US20190350935A1 (en) 2019-11-21
EP2885003A1 (en) 2015-06-24
CN105050623A (zh) 2015-11-11
JP2018035188A (ja) 2018-03-08
AU2013302702A1 (en) 2015-02-19
US20150216870A1 (en) 2015-08-06
JP2020079243A (ja) 2020-05-28
AU2019226212B2 (en) 2020-05-14
AU2016238903A1 (en) 2016-10-27
RU2705095C2 (ru) 2019-11-05
US20220280523A1 (en) 2022-09-08
CA2879704A1 (en) 2014-02-20
IN2015DN00528A (enExample) 2015-06-26
AU2019226212A1 (en) 2019-09-26
RU2015108755A (ru) 2016-10-10
CN105050623B (zh) 2018-06-12
JP6970217B2 (ja) 2021-11-24
MX369518B (es) 2019-11-11
KR20150043328A (ko) 2015-04-22
HK1211476A1 (en) 2016-05-27
MX2015002005A (es) 2015-10-08
BR112015002528A2 (pt) 2018-05-22
EP2885003B1 (en) 2021-09-29
ES2901712T3 (es) 2022-03-23
JP2015529194A (ja) 2015-10-05

Similar Documents

Publication Publication Date Title
KR102245985B1 (ko) Pi3k 억제제와 c-met 억제제의 조합물
JP6855243B2 (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP6058009B2 (ja) Ｐｉ３ｋ−およびｍｅｋ−阻害剤の相乗的な組合せ
JP6479812B2 (ja) 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
US20160129003A1 (en) Pharmaceutical Combinations
TW201639578A (zh) 阿吡莫德之活性代謝物及其用途
KR20120096869A (ko) 포스포이노시티드 ３-키나제 억제제 및 항당뇨병 화합물의 조합물
KR20180073674A (ko) 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
KR101739158B1 (ko) 조합물
HK1214135A1 (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
HK1214135B (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240424

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240424